NEWS

Six major pharmaceutical projects won the China Patent Gold Award

Release time:

2018-01-02 01:40

Recently, the 19th China Patent Award Presentation Conference co-sponsored by the State Intellectual Property Office of China and the World Intellectual Property Organization was held in Beijing. It is reported that this year's China Patent Award has selected 20 Chinese patent gold awards, of which 6 are related to medicine.

 

Serial Number

Patent Number

Patent Name

1

ZL03139760.3

Group of benzamides with differentiation and antiproliferative activity
Protein deacetylase inhibitor and pharmaceutical preparation thereof

2

ZL200510073595.4

Angiogenesis inhibiting fusion protein and use thereof

3

ZL200510086831.6

A Small Volume and Low Power Consumption Permanent Magnet Biased Outer Rotor Radial
magnetic bearing

4

ZL200710054044.2

Semi-rigid base pavement disease detection and polymer grouting
Maintenance Method

5

ZL200710121059.6

Method for producing polycrystalline silicon

6

ZL200710137548.0

2 '-fluorine -4'-substituted nucleoside analog, preparation thereof
law and application

7

ZL200810072864.9

Method of continuous saponification of grease using a device

8

ZL200910152771.1

Preparation method of 2,4, 5-trifluorophenylacetic acid

9

ZL201010166226.0

Short distance communication method and system

10

ZL201110006357.7

A highly safe cinepazide pharmaceutical composition and
Its preparation method and its application

11

ZL201110270394.9

An Early Warning Method for Overhead Transmission Line Lightning Flashover

12

ZL201110437651.3

Relay method for wireless relay device and wireless medium
Following equipment

13

ZL201210116432.X

A three-level dual-mode space vector overmodulation method
and its system

14

ZL201210488806.0

linear compressor

15

ZL201310022078.9

rhG-CSF drug combination modified by polyethylene glycol
material and its preparation method

16

ZL201310157526.6

Manufacturing method of super capacitor

17

ZL201310556488.1

Cyclone dry pulverized coal gasifier

18

ZL201410195318.X

Real Vehicle Impact Test System for Rail Vehicles

19

ZL201510138254.4

An Intensive DC Ice-melting Device Topology

20

ZL201520269105.7

Microwave frequency conversion circuit and microwave frequency converter

 

Briefly introduce 4 of them:

1. Benzamide histone deacetylase inhibitor with differentiation and antiproliferative activity and pharmaceutical preparation thereof

Developed by Shenzhen Microchip Biotechnology Co., Ltd., it has overcome the difficulties in the treatment of existing drugs, broken the record of zero overseas authorization of original drugs in China, and filled the gap in the industry. In 2015, the core compound of the patent was officially listed, and the first indication was peripheral T-cell lymphoma.

2. Angiogenesis inhibiting fusion protein and use thereof

It was developed by Chengdu Kanghong Biotechnology Co., Ltd. for 10 years and applied to the therapeutic drug "Lang Mu. The drug was launched in April 2014. Its effect on improving patients' vision is more significant, the duration of action is longer, and the frequency of administration is lower when patients are treated.

3. 2 '-fluorine -4'-substituted nucleoside analog, preparation method and application thereof

After long-term research, the team led by Professor Chang Junbiao of Zhengzhou University has synthesized the effective antiviral compound azvudine (FNC), that is, "2 '-fluoro-4'-substituted nucleoside analogs, their preparation methods and applications". This is a new anti-AIDS class I drug with independent intellectual property rights in my country, which can effectively inhibit the replication of HIV in the body.

4. Preparation method of 2,4, 5-trifluorophenylacetic acid

By Zhejiang Yongtai Technology Co., Ltd. after years of independent research and development. Its product 2,4,5-trifluorophenylacetic acid is a key intermediate of Sitagliptin (trade name "Renovi"), a patented drug for diabetes in the United States, and is mainly used to improve blood sugar control in patients with type II diabetes. The industrialization of this patent is conducive to the rapid response of domestic pharmaceutical companies to the sitagliptin drug market, and solves the problems of long-term dependence on imported drugs for Chinese patients with type 2 diabetes, high cost, and most patients cannot afford drugs.

News source:http://news.bioon.com/article/6714878.html

This news was re-edited and reorganized by the Huaxun team and added analytical comments.